• Investors
  • News
  • Subscribe
Hit enter to search or ESC to close
Cardax, Inc. | CDXI
  • About Us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • ZanthoSyn®
    • CDX-101
    • CDX-301
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
Cardax, Inc. | CDXI

Press Releases

Investor Relations
Investors
  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Profile
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

HVCA honors David G. Watumull of Cardax as Life Science Entrepreneur of the Year

Feb 27, 2015

Capsugel and Cardax to Collaborate on Development of Proprietary Astaxanthin Products

Aug 19, 2014

Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors

Jun 17, 2014

Recent Studies Further Demonstrate Astaxanthin’s Potential as a Safe and Effective Anti-Inflammatory

May 19, 2014

Hawaii Business Features Cardax in 'Hawaii-Born Pill: The Next Wonder Drug?'

Apr 22, 2014

Cardax Launches Digital Corporate Communication Channels

Apr 22, 2014

Koffee Korner Inc. Completes Merger With Cardax Pharma, Inc.

Feb 7, 2014

Cardax Pharma, Inc. Enters Into a Definitive Merger Agreement With Koffee Korner, Inc.

Nov 29, 2013

Cardax to Be Granted Chinese Patent Protection for Lead Compound

Aug 28, 2012

Cardax Chief Medical Officer and EVP, Dr. Fredric J. Pashkow, Dies

Dec 21, 2011
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9

    News / Events

    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
    Subscribe to Receive Updates by E-Mail Cardax News Alerts

    Recent News

    • Cardax Announces Breakthrough Longevity Results with ZanthoSyn® in NIH-Funded StudyDecember 6, 2023
    • Cardax Refocuses on ZanthoSyn® Consumer Health BusinessAugust 31, 2021
    • Cardax Voluntarily Suspends SEC Reporting ObligationsAugust 11, 2021

    *These statements have not been evaluated by the Food and Drug Administration.
    This product is not intended to diagnose, treat, cure, or prevent any disease.

    © 2025 Cardax, Inc. | Disclaimer and Terms of Use | Accessibility Statement

    • About Us
      • Corporate Overview
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
      • Company History
    • Astaxanthin
      • Overview
        • Astaxanthin Overview
        • History and Background
        • Safety
        • Mechanism of Action
        • Synthetic vs. Natural Astaxanthin
      • Research in Key Addressable Markets
      • Scientific Literature
    • Programs
      • Product Platform
      • Commercialization Strategy
      • ZanthoSyn®
      • CDX-101
      • CDX-301
      • CHASE Clinical Trial
      • Intellectual Property
    • Newsroom
    • Investors
      • Investor Overview
      • News / Events
      • Company Information
      • Financial Information
      • Stock Information
      • SEC Filings
      • Corporate Governance
    • Contact Us
    • Investors
    • News
    • Subscribe